Menu Search
Equities

Esperion Therapeutics Inc

ESPR:NMQ

Esperion Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.28
  • Today's Change0.17 / 8.06%
  • Shares traded8.95m
  • 1 Year change+130.09%
  • Beta0.9379
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Esperion Therapeutics Inc grew revenues 54.14% from 75.48m to 116.33m while net income improved from a loss of 233.66m to a smaller loss of 209.25m.
Gross margin81.58%
Net profit margin-29.37%
Operating margin-12.45%
Return on assets-32.41%
Return on equity--
Return on investment-74.85%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Esperion Therapeutics Inc fell by 42.53m. Cash Flow from Financing totalled 50.46m or 43.38% of revenues. In addition the company used 135.49m for operations while cash from investing totalled 42.50m.
Cash flow per share-0.5058
Price/Cash flow per share--
Book value per share-1.89
Tangible book value per share-1.89
More ▼

Balance sheet in USDView more

Esperion Therapeutics Inc uses little or no debt in its capital structure.
Current ratio1.85
Quick ratio1.37
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.